Javascript must be enabled to continue!
Biological effective dose, cumulative radiation dose, risk of malignancy and mortality rate estimation in adult patients who have a history of cancer and exposed to recurrent computed tomography
View through CrossRef
Computed tomography is commonly used for the initial diagnosis of a tumour to provide information about the stage of cancer & to assess whether the disease is responding to treatment. Leukemia & solid tumour may have developed as a result of exposure to a low dose of diagnostic ionizing radiation so another primary tumour may develop as a result of radiation exposure. We used information in the patient sheet to measure patient effective radiation dose(E) in millisievert (mSv) & calculate cumulative dose by summation of dose over three years, estimated life attributed risk & mortality rate. The results of the current study revealed that from 50 patients 37 (74%) of them were female & 13 (26%) of them were male, age range 23- 80yr, breast cancer was the commonest cause of malignancy follow by lung cancer. Cumulative dose in mSv/yr rang 12-80 mSv, about 43(86%) of our patients exposed to more than 20mSv /yr & 7(14%) of them expose to 20 & less than 20 per year. Collective dose in three years’ range was 35-250 mSv mean 97 ± 37 Estimated radiological effective dose was more than 100 mSv in 22 (44%) per three years & 28(56%) of them had less than 100mSv. Life attributed risk for incidence of cancers was 1:285 -1:40 & mortality rate 0.21%-1.5%. A high percentage of patient 86% with cancer receive high radiation dose annually from CT scan more than considerable safe radiation dose for a worker in this field and 44% of our patient expose to cumulative dose more than 100 mSv per three which is also excess allowed dose for the radiological worker.
GP Innovations Pvt. Ltd.
Title: Biological effective dose, cumulative radiation dose, risk of malignancy and mortality rate estimation in adult patients who have a history of cancer and exposed to recurrent computed tomography
Description:
Computed tomography is commonly used for the initial diagnosis of a tumour to provide information about the stage of cancer & to assess whether the disease is responding to treatment.
Leukemia & solid tumour may have developed as a result of exposure to a low dose of diagnostic ionizing radiation so another primary tumour may develop as a result of radiation exposure.
We used information in the patient sheet to measure patient effective radiation dose(E) in millisievert (mSv) & calculate cumulative dose by summation of dose over three years, estimated life attributed risk & mortality rate.
The results of the current study revealed that from 50 patients 37 (74%) of them were female & 13 (26%) of them were male, age range 23- 80yr, breast cancer was the commonest cause of malignancy follow by lung cancer.
Cumulative dose in mSv/yr rang 12-80 mSv, about 43(86%) of our patients exposed to more than 20mSv /yr & 7(14%) of them expose to 20 & less than 20 per year.
Collective dose in three years’ range was 35-250 mSv mean 97 ± 37 Estimated radiological effective dose was more than 100 mSv in 22 (44%) per three years & 28(56%) of them had less than 100mSv.
Life attributed risk for incidence of cancers was 1:285 -1:40 & mortality rate 0.
21%-1.
5%.
A high percentage of patient 86% with cancer receive high radiation dose annually from CT scan more than considerable safe radiation dose for a worker in this field and 44% of our patient expose to cumulative dose more than 100 mSv per three which is also excess allowed dose for the radiological worker.
Related Results
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract
Introduction
Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...
Clinicopathological Features of Indeterminate Thyroid Nodules: A Single-center Cross-sectional Study
Clinicopathological Features of Indeterminate Thyroid Nodules: A Single-center Cross-sectional Study
Abstract
Introduction
Due to indeterminate cytology, Bethesda III is the most controversial category within the Bethesda System for Reporting Thyroid Cytopathology. This study exam...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Abstract
Introduction
Immunoglobulin G4-related disease (IgG4-RD) is a recently identified immune-mediated condition that is debilitating and often overlooked. While IgG4-RD has be...
Coexisting Granulomatous Mastitis and Breast Cancer: A Systematic Review
Coexisting Granulomatous Mastitis and Breast Cancer: A Systematic Review
Abstract
Introduction: Granulomatous mastitis (GM) is a rare inflammatory breast disease that mimics carcinoma. GM can coexist with breast cancer (BC), though the relationship rema...
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract
Introduction
Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

